Business Daily Media

Newsfile

Gene Therapy Market Worth $13.0 Billion by 2024

  • Written by Newsfile

Chicago, Illinois--(Newsfile Corp. - October 20, 2021) - According to the new market research report "Gene Therapy Market by Vectors [Non-viral (Oligonucleotides), Viral (Retroviral (Gammaretroviral, Lentiviral), Adeno-associated], Indication (Cancer, Neurological Diseases), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2024", published by MarketsandMarkets™, the gene therapy market is projected to reach USD 13.0 billion by 2024 from USD 3.8 billion in 2019, at a CAGR of 27.8% from 2019 to 2024.

Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122857962[1]

The high incidence of cancer and other target diseases, availability of reimbursement, and the launch of new products are the major factors driving the growth of the market.

The non-viral vectors segment accounted for the largest share of the market, by vector, in 2018

The Gene Therapy Market, by vector, has been segmented into viral and non-viral vectors. Non-viral vectors accounted for the largest share of the market in 2018. This is mainly attributed to the high market penetration of oligonucleotide-based non-viral vector gene therapies.

Browse in-depth TOC on "Gene Therapy Market"[2]

127 - Tables25 - Figures129 - Pages

The demand for gene therapies for the treatment of cancer is expected to grow at a high rate

Based on indication, the market is segmented into neurological diseases, cancer, hepatological diseases, Duchenne muscular dystrophy, and other indications. The neurological diseases segment accounted for the largest share of the market in 2018. However, the cancer segment is estimated to grow at the highest CAGR during the forecast period owing to the increasing incidence of cancer and the rising demand for CAR T-cell therapies.

Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=122857962[3]

North America is the largest regional market for gene therapy products

The global Gene Therapy Market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America accounted for the largest share of the market, followed by Europe. Moreover, the North American market is estimated to register the highest growth rate during the forecast period. Factors such as the rising prevalence of chronic diseases, high healthcare expenditure, presence of advanced healthcare infrastructure, favorable reimbursement scenario, and the presence of major market players in the region are driving market growth in North America.

The prominent players operating in the Gene Therapy Market include Biogen (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Spark Therapeutics, Inc. (US), MolMed S.p.A. (Itlay), Orchard Therapeutics plc. (UK), Sibiono GeneTech Co. Ltd. (China), Alnylam Pharmaceuticals, Inc. (US), Human Stem Cells Institute (Russia), AnGes, Inc. (Japan), Dynavax Technologies (US), Jazz Pharmaceuticals, Inc. (Ireland), and Akcea Therapeutics (US).

About MarketsandMarkets™:

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:Mr. Ashish MehraMarketsandMarkets™ INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA : +1-888-600-6441Email: sales@marketsandmarkets.com[4]Content Source: https://www.marketsandmarkets.com/PressReleases/gene-therapy.asp[5]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/100304[6]

Read more https://www.newsfilecorp.com/release/100304/Gene-Therapy-Market-Worth-13.0-Billion-by-2024-Exclusive-Report-by-MarketsandMarketsTM

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion